

# Global and China HR+/HER2- Breast Cancer Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/GC05547F4567EN.html>

Date: August 2020

Pages: 93

Price: US\$ 3,900.00 (Single User License)

ID: GC05547F4567EN

## Abstracts

Global HR+/HER2- Breast Cancer Scope and Market Size

HR+/HER2- Breast Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global HR+/HER2- Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into

CDK4/6 Inhibitors

PARP Inhibitors

PI3K Inhibitor

Others

Market segment by Application, split into

Hospitals

Cancer Center

Medical Research and Academic Institutions

Ambulatory Surgical Centers

Others

Based on regional and country-level analysis, the HR+/HER2- Breast Cancer market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global HR+/HER2- Breast Cancer market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The key players covered in this study

Jiangsu HengRui Medicine

Odonate Therapeutics

Radius Pharmaceuticals

Immunomedics

Roche Group

Syndax Pharmaceuticals

Merck

Eagle Pharmaceuticals

Merrimack Pharmaceuticals

GlaxoSmithKline

Millennium Pharmaceuticals

Bayer

## Contents

### 1 REPORT OVERVIEW

#### 1.1 Study Scope

#### 1.2 Market Analysis by Type

##### 1.2.1 Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026

##### 1.2.2 CDK4/6 Inhibitors

##### 1.2.3 PARP Inhibitors

##### 1.2.4 PI3K Inhibitor

##### 1.2.5 Others

#### 1.3 Market by Application

##### 1.3.1 Global HR+/HER2- Breast Cancer Market Share by Application: 2020 VS 2026

##### 1.3.2 Hospitals

##### 1.3.3 Cancer Center

##### 1.3.4 Medical Research and Academic Institutions

##### 1.3.5 Ambulatory Surgical Centers

##### 1.3.6 Others

#### 1.4 Study Objectives

#### 1.5 Years Considered

### 2 GLOBAL GROWTH TRENDS

#### 2.1 Global HR+/HER2- Breast Cancer Market Perspective (2015-2026)

#### 2.2 Global HR+/HER2- Breast Cancer Growth Trends by Regions

##### 2.2.1 HR+/HER2- Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026

##### 2.2.2 HR+/HER2- Breast Cancer Historic Market Share by Regions (2015-2020)

##### 2.2.3 HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2021-2026)

#### 2.3 Industry Trends and Growth Strategy

##### 2.3.1 Market Trends

##### 2.3.2 Market Drivers

##### 2.3.3 Market Challenges

##### 2.3.4 Market Restraints

### 3 COMPETITION LANDSCAPE BY KEY PLAYERS

#### 3.1 Global Top HR+/HER2- Breast Cancer Players by Market Size

##### 3.1.1 Global Top HR+/HER2- Breast Cancer Players by Revenue (2015-2020)

3.1.2 Global HR+/HER2- Breast Cancer Revenue Market Share by Players  
(2015-2020)

3.2 Global HR+/HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2  
and Tier 3)

3.3 Players Covered: Ranking by HR+/HER2- Breast Cancer Revenue

3.4 Global HR+/HER2- Breast Cancer Market Concentration Ratio

3.4.1 Global HR+/HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by HR+/HER2- Breast Cancer Revenue in  
2019

3.5 Key Players HR+/HER2- Breast Cancer Area Served

3.6 Key Players HR+/HER2- Breast Cancer Product Solution and Service

3.7 Date of Enter into HR+/HER2- Breast Cancer Market

3.8 Mergers & Acquisitions, Expansion Plans

#### **4 HR+/HER2- BREAST CANCER BREAKDOWN DATA BY TYPE (2015-2026)**

4.1 Global HR+/HER2- Breast Cancer Historic Market Size by Type (2015-2020)

4.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2021-2026)

#### **5 HR+/HER2- BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)**

5.1 Global HR+/HER2- Breast Cancer Historic Market Size by Application (2015-2020)

5.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Application  
(2021-2026)

#### **6 NORTH AMERICA**

6.1 North America HR+/HER2- Breast Cancer Market Size (2015-2026)

6.2 North America HR+/HER2- Breast Cancer Market Size by Type (2015-2020)

6.3 North America HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

6.4 North America HR+/HER2- Breast Cancer Market Size by Country (2015-2020)

6.4.1 United States

6.4.2 Canada

#### **7 EUROPE**

7.1 Europe HR+/HER2- Breast Cancer Market Size (2015-2026)

7.2 Europe HR+/HER2- Breast Cancer Market Size by Type (2015-2020)

7.3 Europe HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

7.4 Europe HR+/HER2- Breast Cancer Market Size by Country (2015-2020)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

7.4.6 Nordic

7.4.7 Rest of Europe

## **8 CHINA**

8.1 China HR+/HER2- Breast Cancer Market Size (2015-2026)

8.2 China HR+/HER2- Breast Cancer Market Size by Type (2015-2020)

8.3 China HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

8.4 China HR+/HER2- Breast Cancer Market Size by Region (2015-2020)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 Southeast Asia

8.4.5 India

8.4.6 Australia

8.4.7 Rest of Asia-Pacific

## **9 JAPAN**

9.1 Japan HR+/HER2- Breast Cancer Market Size (2015-2026)

9.2 Japan HR+/HER2- Breast Cancer Market Size by Type (2015-2020)

9.3 Japan HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

9.4 Japan HR+/HER2- Breast Cancer Market Size by Country (2015-2020)

9.4.1 Mexico

9.4.2 Brazil

## **10 SOUTHEAST ASIA**

10.1 Southeast Asia HR+/HER2- Breast Cancer Market Size (2015-2026)

10.2 Southeast Asia HR+/HER2- Breast Cancer Market Size by Type (2015-2020)

10.3 Southeast Asia HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

## 10.4 Southeast Asia HR+/HER2- Breast Cancer Market Size by Country (2015-2020)

- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 UAE
- 10.4.4 Rest of Middle East & Africa

## 11 KEY PLAYERS PROFILES

### 11.1 Jiangsu HengRui Medicine

- 11.1.1 Jiangsu HengRui Medicine Company Details
- 11.1.2 Jiangsu HengRui Medicine Business Overview
- 11.1.3 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Introduction
- 11.1.4 Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2015-2020))
- 11.1.5 Jiangsu HengRui Medicine Recent Development

### 11.2 Odonate Therapeutics

- 11.2.1 Odonate Therapeutics Company Details
- 11.2.2 Odonate Therapeutics Business Overview
- 11.2.3 Odonate Therapeutics HR+/HER2- Breast Cancer Introduction
- 11.2.4 Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
- 11.2.5 Odonate Therapeutics Recent Development

### 11.3 Radius Pharmaceuticals

- 11.3.1 Radius Pharmaceuticals Company Details
- 11.3.2 Radius Pharmaceuticals Business Overview
- 11.3.3 Radius Pharmaceuticals HR+/HER2- Breast Cancer Introduction
- 11.3.4 Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
- 11.3.5 Radius Pharmaceuticals Recent Development

### 11.4 Immunomedics

- 11.4.1 Immunomedics Company Details
- 11.4.2 Immunomedics Business Overview
- 11.4.3 Immunomedics HR+/HER2- Breast Cancer Introduction
- 11.4.4 Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
- 11.4.5 Immunomedics Recent Development

### 11.5 Roche Group

- 11.5.1 Roche Group Company Details
- 11.5.2 Roche Group Business Overview
- 11.5.3 Roche Group HR+/HER2- Breast Cancer Introduction



- 11.5.4 Roche Group Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
- 11.5.5 Roche Group Recent Development
- 11.6 Syndax Pharmaceuticals
  - 11.6.1 Syndax Pharmaceuticals Company Details
  - 11.6.2 Syndax Pharmaceuticals Business Overview
  - 11.6.3 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Introduction
  - 11.6.4 Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 11.6.5 Syndax Pharmaceuticals Recent Development
- 11.7 Merck
  - 11.7.1 Merck Company Details
  - 11.7.2 Merck Business Overview
  - 11.7.3 Merck HR+/HER2- Breast Cancer Introduction
  - 11.7.4 Merck Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 11.7.5 Merck Recent Development
- 11.8 Eagle Pharmaceuticals
  - 11.8.1 Eagle Pharmaceuticals Company Details
  - 11.8.2 Eagle Pharmaceuticals Business Overview
  - 11.8.3 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Introduction
  - 11.8.4 Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 11.8.5 Eagle Pharmaceuticals Recent Development
- 11.9 Merrimack Pharmaceuticals
  - 11.9.1 Merrimack Pharmaceuticals Company Details
  - 11.9.2 Merrimack Pharmaceuticals Business Overview
  - 11.9.3 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Introduction
  - 11.9.4 Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 11.9.5 Merrimack Pharmaceuticals Recent Development
- 11.10 GlaxoSmithKline
  - 11.10.1 GlaxoSmithKline Company Details
  - 11.10.2 GlaxoSmithKline Business Overview
  - 11.10.3 GlaxoSmithKline HR+/HER2- Breast Cancer Introduction
  - 11.10.4 GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 11.10.5 GlaxoSmithKline Recent Development
- 11.11 Millennium Pharmaceuticals
  - 10.11.1 Millennium Pharmaceuticals Company Details
  - 10.11.2 Millennium Pharmaceuticals Business Overview

- 10.11.3 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Introduction
- 10.11.4 Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
- 10.11.5 Millennium Pharmaceuticals Recent Development
- 11.12 Bayer
  - 10.12.1 Bayer Company Details
  - 10.12.2 Bayer Business Overview
  - 10.12.3 Bayer HR+/HER2- Breast Cancer Introduction
  - 10.12.4 Bayer Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
  - 10.12.5 Bayer Recent Development

## **12ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **13APPENDIX**

- 13.1 Research Methodology
  - 13.1.1 Methodology/Research Approach
  - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 3. Key Players of CDK4/6 Inhibitors

Table 4. Key Players of PARP Inhibitors

Table 5. Key Players of PI3K Inhibitor

Table 6. Key Players of Others

Table 7. Global HR+/HER2- Breast Cancer Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 8. Global HR+/HER2- Breast Cancer Market Size by Regions (US\$ Million): 2020 VS 2026

Table 9. Global HR+/HER2- Breast Cancer Market Size by Regions (2015-2020) (US\$ Million)

Table 10. Global HR+/HER2- Breast Cancer Market Share by Regions (2015-2020)

Table 11. Global HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 12. Global HR+/HER2- Breast Cancer Market Share by Regions (2021-2026)

Table 13. HR+/HER2- Breast Cancer Market Market Trends

Table 14. HR+/HER2- Breast Cancer Market Drivers

Table 15. HR+/HER2- Breast Cancer Market Challenges

Table 16. HR+/HER2- Breast Cancer Market Restraints

Table 17. Global HR+/HER2- Breast Cancer Revenue by Players (2015-2020) (US\$ Million)

Table 18. Global HR+/HER2- Breast Cancer Market Share by Players (2015-2020)

Table 19. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2019)

Table 20. Global HR+/HER2- Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players HR+/HER2- Breast Cancer Product Solution and Service

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global HR+/HER2- Breast Cancer Market Size by Type (2015-2020) (US\$ Million)

Table 25. Global HR+/HER2- Breast Cancer Market Size Share by Type (2015-2020)

Table 26. Global HR+/HER2- Breast Cancer Revenue Market Share by Type (2021-2026)

Table 27. Global HR+/HER2- Breast Cancer Market Size Share by Application (2015-2020)

Table 28. Global HR+/HER2- Breast Cancer Market Size by Application (2015-2020) (US\$ Million)

Table 29. Global HR+/HER2- Breast Cancer Market Size Share by Application (2021-2026)

Table 30. North America HR+/HER2- Breast Cancer Market Size by Type (2015-2020) (US\$ Million)

Table 31. North America HR+/HER2- Breast Cancer Market Share by Type (2015-2020)

Table 32. North America HR+/HER2- Breast Cancer Market Size by Application (2015-2020) (US\$ Million)

Table 33. North America HR+/HER2- Breast Cancer Market Share by Application (2015-2020)

Table 34. North America HR+/HER2- Breast Cancer Market Size by Country (US\$ Million) (2015-2020)

Table 35. North America HR+/HER2- Breast Cancer Market Share by Country (2015-2020)

Table 36. Europe HR+/HER2- Breast Cancer Market Size by Type (2015-2020) (US\$ Million)

Table 37. Europe HR+/HER2- Breast Cancer Market Share by Type (2015-2020)

Table 38. Europe HR+/HER2- Breast Cancer Market Size by Application (2015-2020) (US\$ Million)

Table 39. Europe HR+/HER2- Breast Cancer Market Share by Application (2015-2020)

Table 40. Europe HR+/HER2- Breast Cancer Market Size by Country (US\$ Million) (2015-2020)

Table 41. Europe HR+/HER2- Breast Cancer Market Share by Country (2015-2020)

Table 42. China HR+/HER2- Breast Cancer Market Size by Type (2015-2020) (US\$ Million)

Table 43. China HR+/HER2- Breast Cancer Market Share by Type (2015-2020)

Table 44. China HR+/HER2- Breast Cancer Market Size by Application (2015-2020) (US\$ Million)

Table 45. China HR+/HER2- Breast Cancer Market Share by Application (2015-2020)

Table 46. China HR+/HER2- Breast Cancer Market Size by Region (US\$ Million) (2015-2020)

Table 47. China HR+/HER2- Breast Cancer Market Share by Region (2015-2020)

Table 48. Japan HR+/HER2- Breast Cancer Market Size by Type (2015-2020) (US\$ Million)

Table 49. Japan HR+/HER2- Breast Cancer Market Share by Type (2015-2020)

Table 50. Japan HR+/HER2- Breast Cancer Market Size by Application (2015-2020)

(US\$ Million)

Table 51. Japan HR+/HER2- Breast Cancer Market Share by Application (2015-2020)

Table 52. Japan HR+/HER2- Breast Cancer Market Size by Country (US\$ Million)  
(2015-2020)

Table 53. Japan HR+/HER2- Breast Cancer Market Share by Country (2015-2020)

Table 54. Southeast Asia HR+/HER2- Breast Cancer Market Size by Type (2015-2020)  
(US\$ Million)

Table 55. Southeast Asia HR+/HER2- Breast Cancer Market Share by Type  
(2015-2020)

Table 56. Southeast Asia HR+/HER2- Breast Cancer Market Size by Application  
(2015-2020) (US\$ Million)

Table 57. Southeast Asia HR+/HER2- Breast Cancer Market Share by Application  
(2015-2020)

Table 58. Southeast Asia HR+/HER2- Breast Cancer Market Size by Country (US\$  
Million) (2015-2020)

Table 59. Southeast Asia HR+/HER2- Breast Cancer Market Share by Country  
(2015-2020)

Table 60. Jiangsu HengRui Medicine Company Details

Table 61. Jiangsu HengRui Medicine Business Overview

Table 62. Jiangsu HengRui Medicine Product

Table 63. Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business  
(2015-2020) (US\$ Million)

Table 64. Jiangsu HengRui Medicine Recent Development

Table 65. Odonate Therapeutics Company Details

Table 66. Odonate Therapeutics Business Overview

Table 67. Odonate Therapeutics Product

Table 68. Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business  
(2015-2020) (US\$ Million)

Table 69. Odonate Therapeutics Recent Development

Table 70. Radius Pharmaceuticals Company Details

Table 71. Radius Pharmaceuticals Business Overview

Table 72. Radius Pharmaceuticals Product

Table 73. Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business  
(2015-2020) (US\$ Million)

Table 74. Radius Pharmaceuticals Recent Development

Table 75. Immunomedics Company Details

Table 76. Immunomedics Business Overview

Table 77. Immunomedics Product

Table 78. Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2015-2020)

(US\$ Million)

Table 79. Immunomedics Recent Development

Table 80. Roche Group Company Details

Table 81. Roche Group Business Overview

Table 82. Roche Group Product

Table 83. Roche Group Revenue in HR+/HER2- Breast Cancer Business (2015-2020)

(US\$ Million)

Table 84. Roche Group Recent Development

Table 85. Syndax Pharmaceuticals Company Details

Table 86. Syndax Pharmaceuticals Business Overview

Table 87. Syndax Pharmaceuticals Product

Table 88. Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 89. Syndax Pharmaceuticals Recent Development

Table 90. Merck Company Details

Table 91. Merck Business Overview

Table 92. Merck Product

Table 93. Merck Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 94. Merck Recent Development

Table 95. Eagle Pharmaceuticals Business Overview

Table 96. Eagle Pharmaceuticals Product

Table 97. Eagle Pharmaceuticals Company Details

Table 98. Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 99. Eagle Pharmaceuticals Recent Development

Table 100. Merrimack Pharmaceuticals Company Details

Table 101. Merrimack Pharmaceuticals Business Overview

Table 102. Merrimack Pharmaceuticals Product

Table 103. Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 104. Merrimack Pharmaceuticals Recent Development

Table 105. GlaxoSmithKline Company Details

Table 106. GlaxoSmithKline Business Overview

Table 107. GlaxoSmithKline Product

Table 108. GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 109. GlaxoSmithKline Recent Development

Table 110. Millennium Pharmaceuticals Company Details

Table 111. Millennium Pharmaceuticals Business Overview

Table 112. Millennium Pharmaceuticals Product

Table 113. Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 114. Millennium Pharmaceuticals Recent Development

Table 115. Bayer Company Details

Table 116. Bayer Business Overview

Table 117. Bayer Product

Table 118. Bayer Revenue in HR+/HER2- Breast Cancer Business (2015-2020) (US\$ Million)

Table 119. Bayer Recent Development

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global HR+/HER2- Breast Cancer Market Share by Type: 2020 VS 2026

Figure 2. CDK4/6 Inhibitors Features

Figure 3. PARP Inhibitors Features

Figure 4. PI3K Inhibitor Features

Figure 5. Others Features

Figure 6. Global HR+/HER2- Breast Cancer Market Share by Application: 2020 VS 2026

Figure 7. Hospitals Case Studies

Figure 8. Cancer Center Case Studies

Figure 9. Medical Research and Academic Institutions Case Studies

Figure 10. Ambulatory Surgical Centers Case Studies

Figure 11. Others Case Studies

Figure 12. HR+/HER2- Breast Cancer Report Years Considered

Figure 13. Global HR+/HER2- Breast Cancer Market Size (US\$ Million), YoY Growth 2015-2026

Figure 14. Global HR+/HER2- Breast Cancer Market Share by Regions: 2020 VS 2026

Figure 15. Global HR+/HER2- Breast Cancer Market Share by Regions (2021-2026)

Figure 16. Global HR+/HER2- Breast Cancer Market Share by Players in 2019

Figure 17. Global Top HR+/HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HR+/HER2- Breast Cancer as of 2019)

Figure 18. The Top 10 and 5 Players Market Share by HR+/HER2- Breast Cancer Revenue in 2019

Figure 19. North America HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 20. United States HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 21. Canada HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 22. Europe HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 23. Germany HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 24. France HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 25. U.K. HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) &



(US\$ Million)

Figure 26. Italy HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 27. Russia HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 28. Nordic HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 29. Rest of Europe HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 30. Asia-Pacific HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 31. China HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 32. Japan HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 33. South Korea HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 34. Southeast Asia HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 35. India HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 36. Australia HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 37. Rest of Asia-Pacific HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 38. Latin America HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 39. Mexico HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 40. Brazil HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 41. Middle East & Africa HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 42. Turkey HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 43. Saudi Arabia HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 44. UAE HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 45. Rest of Middle East & Africa HR+/HER2- Breast Cancer Market Size YoY Growth (2015-2026) & (US\$ Million)

Figure 46. Jiangsu HengRui Medicine Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 47. Odonate Therapeutics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 48. Radius Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 49. Immunomedics Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 50. Roche Group Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 51. Syndax Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 52. Merck Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 53. Eagle Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 54. Merrimack Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 55. GlaxoSmithKline Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 56. Millennium Pharmaceuticals Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 57. Bayer Revenue Growth Rate in HR+/HER2- Breast Cancer Business (2015-2020)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

## I would like to order

Product name: Global and China HR+/HER2- Breast Cancer Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/GC05547F4567EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC05547F4567EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

